The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.12 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.21 — no flag raisedOK
- Earnings quality 91/100 — accruals in line with cashOK
Latest filings
- 6-K · Company announcement (foreign filer)2026-03-27
- 6-K · Company announcement (foreign filer)2026-03-18
- 6-K · Company announcement (foreign filer)2026-01-16
- 6-K · Company announcement (foreign filer)2025-12-31
- 6-K · Company announcement (foreign filer)2025-12-17
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Cellyan Biotechnology Co., Ltd, every answer cited🔒
- The Intelligence Brief — added when Cellyan Biotechnology Co., Ltd's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.